Bangavax
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | mRNA |
| Clinical data | |
| Other names | Bancovid |
| Routes of administration | Intramuscular |
| ATC code |
|
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
Bangavax, also known as Bancovid, is a COVID-19 vaccine candidate developed by a Bangladeshi pharmaceutical company Globe Biotech Limited.[1][2][3][4][5][6] The vaccine was initially called Bancovid.[7] As of May 2021, Globe Biotech is awaiting for approval to conduct the first clinical trial.
History[edit]
On 2 July 2020, Globe Biotech Limited announced to be the first company from Bangladesh to have a Covid-19 vaccine under development.[1] The lone Bangladeshi company actually developed three COVID-19 vaccine candidates with different technologies.[8] The company named the mRNA based vaccine as Bancovid then renamed to Bangavax.[7] Globe Biotech took all the necessary steps from December 2020 to January 2021 to get the permission for ethical approval to conduct the first clinical trial of Bangavax.[4] However fate of the Bangavax is still uncertain due to an unknown reason. The Bangladesh government has been criticized for not approval the vaccine even after months to conduct the first clinical trial without any explanation.[9]
It published full research data in Vaccine journal on May 2021.[10]
Bangladesh Medical Research Council approved the human trial of Bangavax. Before proceeding to human trials, they have to apply the vaccine on monkeys or chimpanzees before proceeding to human trials.[11]
References[edit]
- ^ a b "Globe Biotech's Covid-19 vaccine 'BANCOVID' listed by WHO". Daily Sun. 17 October 2020. Retrieved 28 April 2021.
- ^ "'Bangavax' to get approval within a week". dailyobserver. 25 April 2021. Retrieved 28 April 2021.
- ^ "Globe Biotech applies for clinical trial". Prothom Alo. 17 January 2021. Retrieved 28 April 2021.
- ^ a b "Globe Biotech yet to get BMRC nod for human trials". Dhaka Tribune. 22 February 2021. Retrieved 28 April 2021.
- ^ Sumon S (8 January 2021). "Bangladesh joins global COVID-19 vaccine race with Bongavax set for clinical trial". Arab News. Retrieved 28 April 2021.
- ^ Baray JC, Khan MM, Mahmud A, Islam MJ, Myti S, Ali MR, et al. (January 2020). "BANCOVID, the first D614G variant mRNA-based vaccine candidate against SARS-CoV-2 elicits neutralizing antibody and balanced cellular immune response". bioRxiv. doi:10.1101/2020.09.29.319061.
- ^ a b "Globe Biotech to produce vaccine candidate for clinical trial". The Financial Express. 6 January 2021. Retrieved 28 April 2021.
- ^ "3 Covid-19 vaccine candidates by Bangladesh's Globe Biotech enlisted in WHO draft landscape". The Daily Star. 17 October 2020. Retrieved 4 May 2021.
- ^ Masum O (6 May 2021). "Bangavax first buzzed with hope, then fizzled". bdnews24. Retrieved 6 May 2021.
- ^ Nag K, Baray JC, Khan MR, Mahmud A, Islam J, Myti S, et al. (18 May 2021). "An mRNA-based vaccine candidate against SARS-CoV-2 elicits stable immuno-response with single dose". Vaccine X. 39 (23). doi:10.1016/j.vaccine.2021.05.035. PMC 8130517. PMID 34039497.
- ^ "Bangavax Covid vaccin: BMRC gives fresh conditions to Globe Biotech for human trials". Dhaka Tribune. 16 June 2021. Retrieved 16 June 2021.
 |
Scholia has a profile for Bangavax (Q106809739). |
.png){kind=small} | This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |